Challenges and facilitators in the development of orphan and paediatric medicines

We suggest that many of the barriers identified in this report – especially a lack of flexibility and pragmatism in regulatory and reimbursement policies – could be reduced through closer and earlier collaboration between industry and regulators/payers. Such collaboration could reduce uncertainty, time, and costs in the development process and encourage greater developments in the most urgent areas of unmet need.